Criteria for Indicating a Positron Emission Tomography According to Recommended Scenarios
Keywords:
cancer, criteria, Positron emission tomographyAbstract
Introduction: 18-fluoride-deoxyglucose is the most commonly used rafiodrug for positron emission tomography studies. Its introduction in Cuba has resulted in a positive impact on the care of cancer patients, which is valuable when it is estimated that due to the impact caused by the COVID-19 pandemic, mortality from cancer will increase in the coming years.Objective: To present the recommended oncological scenarios for the accurate and effective indication of positron emission tomography with the use of 18-fluorine-deoxyglucose.Development: A review of the biography was carried out, based on meta-analysis and on the authors' own experience by performing hundreds of positron emission tomography scans plus computed tomography initially with imported molecules and then with the nationally produced one. It has been shown that in the recommended scenarios there is evidence of a better diagnosis given by sensitivity and specificity. The information derived from the study has an estimable impact on patient outcomes, either by deciding on more effective therapeutic strategies or by not adopting inefficient practices.Conclusions: The precise indication of positron emission tomography plus computed tomography guarantees better accuracy from diagnosis to follow-up of cancer patients, increases the quality of radiant treatment by allowing better visualization of target volumes, differentiation of risk organs and homogeneity in the delineation of structures.
References
The ICGC/TCGA Pan-cancer analysis of whole genome consortium. Nature.2020; 578:82.
Oliva González, Juan P, Martínez Ramírez, Aldo, & Baum, Richard Paul. (2017). PET/CT applications in oncology. Nucleus, (62), 10-13.
Treglia, Giorgio; Giovanella, Luca. Evidence-based Positron Emission Tomography: Summary of Recent Meta-analyses on PET. Springer Nature, 2020.
MUFACE. Guía PET-TC. Protocolo de Prescripción. Mutualidad General de Funcionarios Civiles del Estado. Madrid, 2011.www.muface.es
IAEA (International Atomic Energy Agency). Appropriate Use of FDG–PET for the Management of Cancer Patients.IAEA Human Health Series. Nº 9. International Atomic Energy Agency. Viena, 2010
MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017Radiology.2017;284(1):228-43.
Wang J, Welch K, Wang L, Kong FM. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-smallcell lung cancer: a meta-analysis. Clin Lung Cancer.2012;13(2):81–9 2020 BOOK_Evidence- basedPositronEmission
Zhang C, Liu J, Tong J, Sun X, Song S, Huang G. 18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC. Nucl Med Commun.2013;34(1):71-7]
He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol. 2014;55(3):309-17
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. Version 3.2022- March 16, 2022.
Pichón-Riviere, Andrés. Tomografía por emisión de positrones (PET) en el seguimiento rutinario de neoplasias seleccionadas. s.l; IECS; jun. 2018.
Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, Salvesen HB, Haldorsen IS. High diagnostic value of 18F-FDG PET/CT in endometrial cancer: systematic review and meta-analysis of the literature. J Nucl Med. 2016;57(6):879-85.
Kakhki VR, Shahriari S, Treglia G, Hasanzadeh M, Zakavi SR, Yousefi Z, et al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesión and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. Int J Gynecol Cancer. 2013;23(9):1536-43.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Uterine Neoplasms. Version 1.2022- November 4, 2021.
Piña-Sanchez et al. Cancer Control.2021;28:1-21
Wong ET, Dmytriw AA, Yu E, Waldron J, Lu L, Fazelzad R, et al. 18 F-FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: a meta-analysis of reported studies. Head Neck. 2019;41(2):551-61
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).Head and Neck Cancer. Version 1.2022- December 8, 2021.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).Testicular Cancer. Version 2.2022- January 4, 2022.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer. Version 1.2022- February 25, 2022.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Rectal Cancer. Version 2.2022- January 11, 2022.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer. Version 2.2022- January 11, 2022.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Soft Tissue Sarcoma. Version 2.2022- May 17, 2022.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).Bone Cancer. Version 2.2022- October 8, 2021.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).Gastrointestina Stromal Tumors (GISTs). Version 1.2022- January 21, 2022.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).Esophageal and Esophagogastric Junction Cancers. Version 2.2022- February 11, 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Lisset Barroso Márquez, Dayana Ugarte Moreno, Daril Gutiérrez Rodríguez, Esteban Alfaro Alonso, Mayka Caridad Guerrero Cancio, Yordanka Martínez Almaguer, Aramis Arrazcaeta Alvarez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
